By GlobalMHSummit.com Research Team
Short answer: the best available evidence does not support ginkgo biloba for preventing dementia or Alzheimer's disease. The largest and longest trial ever run on this specific question — the NIH-funded Ginkgo Evaluation of Memory (GEM) study, which followed more than 3,000 adults for a median of six years — found no difference in dementia rates between the ginkgo group and the placebo group. If “ginkgo for memory” turned up here while searching for a preventive answer, that's the honest starting point.
That doesn't mean there's nothing useful to say about ginkgo, or about memory concerns generally. It means the useful part is being specific about what was actually tested, what wasn't, and what matters more if a memory change is the real concern.
What the research actually shows about ginkgo and dementia prevention
The National Center for Complementary and Integrative Health (NCCIH), part of the NIH, states its position directly: ginkgo “has not been shown to be beneficial for preventing or slowing the progression of dementia.” That conclusion rests mainly on three large studies in older adults with either normal cognition or mild cognitive impairment, the most rigorous of which is GEM.
A few specifics matter here, because they're the difference between a real answer and a marketing one:
- Population: GEM enrolled 3,069 community-dwelling adults ages 72 to 96 who did not already have dementia at baseline — not younger adults, and not people already diagnosed with cognitive impairment.
- Endpoint: The primary outcome was a clinical diagnosis of all-cause dementia or Alzheimer's disease, confirmed by an expert consensus panel using standard diagnostic criteria — not a self-reported “I feel sharper” measure.
- Result: No statistically significant difference in dementia incidence between ginkgo (240 mg/day, as the standardized extract EGb 761) and placebo over a median of roughly six years. Slightly more people developed dementia in the ginkgo group than the placebo group (277 vs. 246), a gap the researchers describe as not statistically meaningful.
- Study quality: This is widely regarded as the best-designed trial on the question — randomized, double-blind, placebo-controlled, with a pre-specified clinical endpoint — which is part of why NCCIH treats the null result as informative rather than inconclusive.
NCCIH also notes a separate, more hedged finding: ginkgo extract “may have a modest benefit for dementia symptoms” once dementia is already present, particularly at higher doses — but the agency adds that the evidence there is inconsistent. That's a different question from prevention in people who don't yet have the disease. A small, short, symptom-focused study in people who already have a diagnosis can't be read as evidence that ginkgo prevents the disease from developing in the first place. That distinction — a prevention endpoint in a large trial versus pilot or symptom data elsewhere — is the one worth holding onto if this topic comes up again.
Interactions worth raising with a pharmacist or physician
Independent of whether ginkgo helps memory, it isn't interaction-free, and the evidence here is more mixed than a simple warning label suggests — which is itself the reason to ask rather than assume either way:
- Anticoagulants and antiplatelet drugs: NCCIH's safety summary states plainly that ginkgo “may increase the risk of bleeding in people who are taking anticoagulant drugs, such as warfarin.” At the same time, a controlled pharmacokinetic study in healthy subjects found that ginkgo, at recommended doses, did not significantly affect warfarin's clotting activity, and a separate systematic review of controlled trials and case reports concluded there is “scant information from case reports or controlled trials to support the suggestion that Ginkgo potentiates the effects of anticoagulant or antiplatelet drugs.” A more recent retrospective review of pharmacy records, however, found a statistically significant correlation between ginkgo-involved drug interactions and both bleeding risk and abnormal coagulation test results. The honest summary: the signal isn't as settled as either “definitely dangerous” or “definitely fine” framing suggests, which is exactly why anyone on blood thinners or antiplatelet medication should raise it with their prescriber rather than decide alone.
- Seizure threshold: Case reports in the clinical literature